Table 1.
Clinical and pathological data
| Age at diagnosis (median) | 44 years | |
|---|---|---|
| Smoking history | Yes | 28.8% (n=17) |
| No | 71.2% (n=42) | |
| Histologic subtype | Squamous cell | 86.4% (n=51) |
| Adenocarcinoma | 13.6% (n=8) | |
| PS | 0 | 28.8% (n=17) |
| 1 | 62.7% (n=32) | |
| 2 | 5.1% (n=3) | |
| 3 | 3.4% (n=2) | |
| 4 | – | |
| CS (FIGO, 2009) | I | 10.1% (n=6) |
| II | 30.5% (n=18) | |
| III | 40.7% (n=24) | |
| IVA | 13.6% (n=8) | |
| IVB | 5.1% (n=3) | |
| Treatament | Surgery (frontline) | 27.1% (n=16) |
| CT-RT | 64% (n=38) | |
| Brachytherapy | 32.2% (n=19) | |
| RT (exclusive) | 16% (n=9) | |
| Endpoint | Progression | 47.5% (n=28) |
| Death | 33.9% (n=20) | |
| Follow-up (median) | 26.2 months | |
Abbreviations: PS, performance status; CS, clinical stage.